Cytyc pays $160million for breast radiation therapy firm
This article was originally published in Clinica
Cytyc has agreed to pay $160m in cash for Proxima Therapeutics, a private company with an FDA-cleared post-lumpectomy targeted radiation therapy system for early-stage breast cancer. Proxima also sells a similar system to treat resected brain tumours, which Cytyc hopes to divest because it does not fit into its focus on women's health. Both products involve the use of a balloon catheter to deliver a radiation source directly to the cavity left following the removal of the tumour.